{
    "name": "asfotase alfa",
    "comment": "Rx",
    "other_names": [
        "Strensiq"
    ],
    "classes": [
        "Enzymes",
        "Metabolic"
    ],
    "source": "https://reference.medscape.com/drug/strensiq-asfotase-alfa-999992",
    "pregnancy": {
        "common": [
            "There are no available human data on asfotase alfa use in pregnant women to inform a drug associated risk",
            "In animal reproduction studies, asfotase alfa administered IV to pregnant rats and rabbits during the period of organogenesis showed no evidence of fetotoxicity, embryo lethality, or teratogenicity at doses causing plasma exposures up to 21 and 24 times, respectively, the exposure at the recommended human dose"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Unknown if distributed in human breast milk"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "None"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Hypersensitivity reactions (rare) reported in clinical trials; reactions have occurred within minutes after subcutaneous administration and have been observed more than 1 year after treatment initiation; monitor and if severe reaction occurs, discontinue treatment and initiate appropriate medical treatment",
                "Localized lipodystrophy, including lipoatrophy and lipohypertrophy, has been reported at injection sites after several months; monitor for proper injection technique and injection site rotation",
                "Patients with HPP are at increased risk for developing ectopic calcifications; in clinical trials, 14 cases (14%) of ectopic calcification of the eye, including the cornea and conjunctiva, and the kidneys (nephrocalcinosis) were reported; there was insufficient information to determine whether or not the reported events were consistent with the disease or associated with asfotase alfa; ophthalmology examinations and renal ultrasounds are recommended at baseline and periodically during treatment",
                "Studies have shown that there is analytical interference between asfotase alfa and laboratory tests that utilize an alkaline phosphatase (ALP)-conjugated test system, rendering erroneous test results in patients treated; recommended that laboratory assays which do not have ALP- conjugate technology be used when testing samples from patients; inform laboratory personnel that patient is being treated with drug and discuss use of testing platform which does not utilize an ALP-conjugated test system"
            ],
            "specific": []
        }
    },
    "interactions": [],
    "adverse effects": [
        {
            "name": "Injection site reactions",
            "percent": "46-90"
        },
        {
            "name": "Lipodystrophy",
            "percent": "18-70"
        },
        {
            "name": "Ectopic calcifications",
            "percent": "5-55"
        },
        {
            "name": "Vomiting",
            "percent": "3-10"
        },
        {
            "name": "emesis",
            "percent": "2-10"
        },
        {
            "name": "Systemic hypersensitivity reactions",
            "percent": null
        }
    ]
}